Precision Neurology's Inflection Point: CND's New Funding Ignites a Diagnostic Revolution

SCOTTSDALE, Ariz. and BOCA RATON, Fla. – August 04, 2026 – For decades, the diagnosis of neurodegenerative diseases like Parkinson's has been a frustrating exercise in ambiguity, relying heavily on clinical observation of symptoms that often appear late and overlap with other conditions. This diagnostic odyssey leaves patients and families in limbo and complicates the development of effective treatments. Now, a significant capital injection into a pioneering diagnostics firm signals that the era of subjective assessment may be ceding ground to a new standard of biological certainty.

CND Life Sciences, a neurodiagnostics company at the forefront of this shift, today announced the completion of a major growth financing round led by S-Curve Partners, an investment firm known for backing healthcare innovators at critical growth junctures. The funding is a powerful vote of confidence in CND's flagship product, the Syn-One Test®, and its mission to bring objective, accessible diagnostics to the complex field of neurology. This move isn't just about one company's balance sheet; it reflects a tectonic shift in the medical landscape, where the advent of disease-modifying therapies is creating an urgent, market-driven demand for early and accurate diagnosis.

A New Diagnostic Paradigm for an Old Problem

At the heart of CND's innovation is the Syn-One Test, the first commercially available laboratory developed test (LDT) to detect phosphorylated alpha-synuclein—the pathological hallmark of Parkinson's disease and related disorders—through a simple skin biopsy. These diseases, collectively known as synucleinopathies, are caused by the misfolding and aggregation of the alpha-synuclein protein in the nervous system. For years, the only way to definitively confirm its presence was through a post-mortem brain autopsy.

The Syn-One Test bypasses this limitation by leveraging the discovery that this abnormal protein is also present in the nerve fibers of the skin. By analyzing small skin samples, the test provides neurologists with direct pathological evidence to support a diagnosis of conditions like Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. This move from symptom-based inference to biomarker-based evidence is a monumental leap forward.

Since its commercial launch in 2020, the test's adoption has been a clear indicator of its clinical utility. According to the company, more than 4,000 clinicians across the United States have utilized Syn-One in the evaluation of over 60,000 patients. This traction demonstrates a powerful demand from frontline neurologists for tools that can provide clarity.

"We are pleased to deepen our relationship with S-Curve Partners and grateful for the continued support of existing investors and shareholders," said Rick Morello, CND's Chief Executive Officer. He noted that the investor confidence "reflects the progress our team has made in expanding clinical adoption and advancing the science behind our scalable neurodiagnostics platform." The new funds are earmarked to sustain this growth, expand commercial initiatives, and fuel further product innovation.

The Strategic Capital Fueling the S-Curve

The investment, led by S-Curve Partners and joined by existing shareholders, is a strategic bet on a company positioned at a crucial "S-curve" inflection point—the moment when an innovation transitions from early adoption to exponential growth. S-Curve Partners, an operator-led firm, specializes in identifying such moments and providing not just capital, but strategic and operational expertise to navigate the rapid scaling phase.

Daniel Livschutz, Founding Partner of S-Curve Partners, articulated the investment thesis clearly: "Neurodegenerative diseases remain among the most underdiagnosed and misdiagnosed conditions in medicine, and as disease-modifying therapies emerge, objective biomarkers will only become more essential for clinicians, patients, researchers, and pharmaceutical companies."

This connection to the therapeutic pipeline is critical. The biopharmaceutical industry is pouring billions into developing drugs that can slow or halt the progression of neurodegenerative diseases. The success of these therapies hinges on identifying the right patients at the earliest possible stage, long before irreversible neurological damage has occurred. A test like Syn-One is not just a diagnostic tool; it is an enabling technology for the entire precision medicine ecosystem in neurology. It helps ensure that patients are correctly diagnosed for clinical trial enrollment and, eventually, for targeted treatment.

"We believe CND has built one of the most differentiated platforms in neurodiagnostics," Livschutz added. The goal of the financing, he explained, is to accelerate its evolution "from a category-defining product to a broader platform supporting earlier diagnosis, disease differentiation, and more personalized care."

From Singular Test to a Multimodal Future

While the Syn-One Test is a breakthrough, the leadership at CND and their investors recognize that the future of neurodiagnostics is not about a single silver-bullet test. The complexity of diseases like Parkinson's demands a more holistic, or "multimodal," approach. The newly secured capital is designated to build out this vision, incorporating the Syn-One platform into a wider array of biomarker capabilities.

This strategy aligns with the leading edge of neurological research, which increasingly points to the power of combining data from multiple sources—such as skin biopsies, blood tests, spinal fluid analysis, and advanced imaging—to create a comprehensive biological signature of a patient's disease. Such a multimodal panel could not only confirm a diagnosis but also help characterize the specific subtype of the disease, predict its progression, and monitor a patient's response to therapy.

"As a neurologist, I am encouraged to see the neuroscience field move toward multimodal biomarkers and earlier intervention," stated Todd Levine, MD, CND's Chief Medical Officer and Co-Founder. "This financing gives us the flexibility to invest in innovation, expand access to the Syn-One platform, and strengthen our pharmaceutical and research relationships."

This evolution from a single test to an integrated data platform is a sophisticated play. It positions CND not just as a test provider, but as a central player in the data infrastructure of precision neurology, collaborating with biopharmaceutical partners on clinical trials and conducting its own research into early disease detection and quantification.

Navigating the Commercial and Regulatory Gauntlet

Despite the scientific promise and fresh funding, the path ahead for CND involves navigating significant hurdles. The first is the challenge of changing established medical practice. For decades, neurologists have been trained to rely on their clinical acumen. Integrating a new biomarker test into this workflow requires extensive education, compelling peer-reviewed evidence, and seamless logistical support—all areas the company plans to bolster with its new capital.

Furthermore, the Syn-One Test is a Laboratory Developed Test (LDT), a category of diagnostics that has historically operated under a different regulatory framework than FDA-approved commercial kits. The regulatory landscape for LDTs is currently in flux, with increasing discussions around greater FDA oversight. While CND's test is supported by a growing body of clinical evidence, navigating this evolving regulatory environment will be a critical task for the company's leadership. The new financing provides a crucial buffer and the resources needed to meet whatever new standards emerge, ensuring the platform's long-term viability and market access.

By securing this strategic financing, CND Life Sciences has not only fortified its own future but has also sent a clear signal to the market. The demand for objective truth in neurology is here, and the capital is flowing to the companies that can deliver it.